Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Eli Lilly’s profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled ...

Eli Lilly And Co (NYSE:LLY ... more than doubled to $3.11 billion from $1.41 billion a year ago. Sales of Verzenio (a breast cancer drug) increased 32% to $1.37 billion, and sales of diabetes ...

Eli Lilly's existing portfolio, excluding incretins, also has potential growth contributors. The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology ...

In particular, Lilly highlighted the momentum behind breast cancer med Verzenio and the SGLT2 inhibitor ... been updated with executive comments from Eli Lilly's fourth-quarter and full-year ...

cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes ...

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... and its breast cancer drug Verzenio, which brought ~$1.6B with ~36% YoY growth. Meanwhile, sales from Type 2 diabetes medication Trulicity ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Eli Lilly's innovative culture and strong financial ... and Jardiance as well as immunology drug Taltz, cancer drug Verzenio, and Alzheimer's drug Kisunla hold the highest sales potential of ...